Critical Care & Emergencies (all articles)
Mitigating inequities and saving lives with ICU triage during the COVID-19 pandemic
9 Feb, 2021 | 01:29h | UTC
ARDS: Contemporary management and novel approaches during COVID-19
9 Feb, 2021 | 01:31h | UTC
Commentary on Twitter
Review Article: Acute Respiratory Distress Syndrome #ARDS: Contemporary Management and Novel Approaches during #COVID19 https://t.co/Hbsuejegos pic.twitter.com/9rOyZmOWpA
— Anesthesiology (@_Anesthesiology) February 5, 2021
RCT: In patients with cirrhosis treated with TIPS, prophylactic rifaximin reduced the risk for Hepatic Encephalopathy
7 Feb, 2021 | 21:10h | UTCThe Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: A Randomized Controlled Trial – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Rifaximin prevents overt hepatic encephalopathy after TIPS – HealthDay
Commentary on Twitter
New findings published in @AnnalsofIM:
In patients with #cirrhosis treated with TIPS, rifaximin was well tolerated and reduced the risk for overt HE. #Rifaximin should therefore be considered for prophylaxis of post-TIPS HE https://t.co/d2p9dfcx3s. pic.twitter.com/M7zwmUxQA3
— Annals of Int Med (@AnnalsofIM) February 2, 2021
RCT: Posaconazole noninferior to voriconazole for primary treatment of invasive aspergillosis
7 Feb, 2021 | 21:00h | UTCPosaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Guideline synopsis: Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy
7 Feb, 2021 | 20:55h | UTCManagement of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy – JAMA (free for a limited period)
Audio Clinical Review: Management of Immunotherapy-Related Toxicities
Original guideline and other resources: NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities
Prospective validation of Canadian TIA Score for subsequent stroke risk after transient ischemic attack
7 Feb, 2021 | 20:54h | UTCSee calculator: Canadian TIA Score
Commentary on Twitter
Jeff Perry is at it again! The ABCD2 score lacks the ability to discriminate low and high risk patients following TIA, so Perry et al. have validated the Canadian TIA Score.
Infographic and bedside calculator: https://t.co/OcbaK1aG3t
Full publication: https://t.co/wt87PKzNkO pic.twitter.com/q3QdgVxp6x
— EM Ottawa (@emergmedottawa) February 4, 2021
Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma
7 Feb, 2021 | 21:32h | UTCSARS-CoV-2 evolution during treatment of chronic infection – Nature
Commentary on Twitter
Just published @nature: The evolution of #SARSCoV2 in an immunocompromised patient, over > 100 days, that markedly accelerated once treated w/ convalescent plasma, with mutations that altered the response to neutralizing antibodies, by @GuptaR_lab https://t.co/SI4QL6BRXe pic.twitter.com/wqI1C2EYjQ
— Eric Topol (@EricTopol) February 5, 2021
SR/MA: ICU mortality from COVID-19 continued to fall in 2020, but improvement is slowing
7 Feb, 2021 | 21:18h | UTCNews release: ICU mortality from COVID-19 continued to fall in 2020, but improvement is slowing – University of Bristol
Original article: Mortality in patients admitted to intensive care with COVID‐19: an updated systematic review and meta‐analysis of observational studies – Anaesthesia
Commentary on Twitter
🔐Has mortality from COVID‐19 in patients admitted to the ICU changed again?@drrichstrong, @adk300, @emirakur and @doctimcook update their previous analysis and find that any fall in mortality rate between June and September appears to have plateaued.
🔗https://t.co/zp8ygzp78A pic.twitter.com/g21p3rcjY6
— 𝘈𝘯𝘢𝘦𝘴𝘵𝘩𝘦𝘴𝘪𝘢 (@Anaes_Journal) February 2, 2021
Cohort study: ECMO in patients with severe respiratory failure from COVID-19
7 Feb, 2021 | 21:16h | UTCRelated: ECMO for COVID-19 patients in Europe and Israel – Intensive Care Medicine
Commentaries on Twitter
#ECMO in #COVID19, multicenter US based study on 5122 critical adults
➡️#ECLS in 3.7%, 66.8% of whom survived to hospital discharge or 60 days
➡️considerably reduced mortality with early ECMO in severe hypoxemic respiratory failure vs conventional approachhttps://t.co/OgS7Q5tctS pic.twitter.com/PO5O8t3l8F— Intensive Care Medicine (@yourICM) February 4, 2021
Online today @yourICM, our important multicenter descriptive and trial emulation work around #ECMO and #COVID19 @BIDMCAnesthesia @DavidLeaf9 @SamanthaSkb273 @_MiguelHernan from the STOP-COVID Investigators https://t.co/DuhWufYqZ3 pic.twitter.com/nXPvKDYMYL
— Shaz Shaefi (@SShaefi) February 2, 2021
What’s the risk of dying from a fast-spreading COVID-19 variant?
7 Feb, 2021 | 21:21h | UTCWhat’s the risk of dying from a fast-spreading COVID-19 variant? – Nature
Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv
Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19
7 Feb, 2021 | 21:13h | UTC“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia
SR/MA: Colistin nephrotoxicity
5 Feb, 2021 | 01:21h | UTC
NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”
5 Feb, 2021 | 01:44h | UTC
Dialysis patients have 4-fold greater risk of dying from COVID-19
5 Feb, 2021 | 01:39h | UTCNews Release: Dialysis patients have 4-fold greater risk of dying from COVID-19 – Canadian Medical Association Journal
Original Study: COVID-19 in patients undergoing long-term dialysis in Ontario – Canadian Medical Association Journal
Randomized trial: Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension
4 Feb, 2021 | 01:18h | UTC
Commentary on Twitter
Does induced hypothermia/targetted temp management improve outcomes in patients with traumatic brain injury?
Maybe or maybe not
But this trial slow to cool, not very cool, underpowered and mod rate of dropout
Prob does not answer questionhttps://t.co/UGRFmUVNV0 pic.twitter.com/c0iDqj2l2e
— Graham Nichol (@grahamnichol) January 29, 2021
German 2021 guideline update on acute therapy and management of anaphylaxis
4 Feb, 2021 | 01:17h | UTC
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
4 Feb, 2021 | 01:39h | UTCInvited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
Meta-analysis: In patients undergoing major visceral/noncardiac surgery, perioperative goal-directed therapy fluid administration reduces complications but has no effect on mortality
3 Feb, 2021 | 01:24h | UTC
Randomized trial: Similar outcomes with Dexmedetomidine or Propofol for sedation in mechanically ventilated adults with sepsis
3 Feb, 2021 | 01:30h | UTCDexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Study finds recommended ICU sedatives equally safe, effective – Vanderbilt University Medical Center AND PulmCrit Wee – MENDS2: Fentanyl or fentanyl for sedation in mechanically ventilated adults with sepsis
Ambulatory management of pulmonary embolism: A comparison of two risk-stratification scores
2 Feb, 2021 | 01:11h | UTC
Resumption of cardiac activity after withdrawal of life-sustaining measures
2 Feb, 2021 | 01:09h | UTCResumption of Cardiac Activity after Withdrawal of Life-Sustaining Measures – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: When is ‘dead’ really dead? What happens after a person ‘flatlines’ – The Conversation
Post severe COVID-19, CT reveals potentially lifetime lung damage in one-thirds of patients
2 Feb, 2021 | 01:19h | UTCOriginal Study: Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia – Radiology
Randomized trial: Conservative fluid management strategy vs. usual care in participants after cardiac surgery
1 Feb, 2021 | 01:39h | UTC
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
New Updates to the Surviving Sepsis Campaign COVID-19 Guidelines
1 Feb, 2021 | 01:56h | UTCAdditional resources: COVID-19 Guidelines – Surviving Sepsis Campaign
Commentary on Twitter
New updates to the #SurvivingSepsis Campaign #COVID19 Guidelines! Includes new recommendations for therapeutics and defines severe vs critical COVID-19.
View the full update in @CritCareMed, more infographics, and recommendations table here: https://t.co/OUuOwGJCR4#SCCMSoMe pic.twitter.com/1RGckdvoIm
— SCCM (@SCCM) January 30, 2021